Amy Kempf

4.0k total citations · 3 hit papers
27 papers, 1.6k citations indexed

About

Amy Kempf is a scholar working on Infectious Diseases, Animal Science and Zoology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Amy Kempf has authored 27 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Infectious Diseases, 6 papers in Animal Science and Zoology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Amy Kempf's work include SARS-CoV-2 and COVID-19 Research (23 papers), COVID-19 Clinical Research Studies (15 papers) and SARS-CoV-2 detection and testing (6 papers). Amy Kempf is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (23 papers), COVID-19 Clinical Research Studies (15 papers) and SARS-CoV-2 detection and testing (6 papers). Amy Kempf collaborates with scholars based in Germany, United Kingdom and France. Amy Kempf's co-authors include Stefan Pöhlmann, Markus Hoffmann, Hans‐Martin Jäck, Luise Graichen, Sebastian Schulz, Martin Sebastian Winkler, Nadine Krüger, Inga Nehlmeier, Georg M. N. Behrens and Anna-Sophie Moldenhauer and has published in prestigious journals such as Cell, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Amy Kempf

25 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

2021 563 citations Markus Hoffmann, Prerna Arora et al. Cell profile →
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic

2021 557 citations Markus Hoffmann, Nadine Krüger et al. Cell profile →
SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency

2024 49 citations Lu Zhang, Amy Kempf et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amy Kempf Germany	12	1.5k	380	206	160	134	27	1.6k
Luise Graichen Germany	10	1.4k 1.0×	356 0.9×	210 1.0×	146 0.9×	130 1.0×	21	1.6k
Maple Wang United States	7	1.7k 1.1×	515 1.4×	243 1.2×	157 1.0×	207 1.5×	9	1.9k
Paul W. Rothlauf United States	9	1.7k 1.1×	535 1.4×	240 1.2×	206 1.3×	184 1.4×	12	2.0k
Frauke Muecksch United States	12	1.3k 0.9×	322 0.8×	151 0.7×	198 1.2×	164 1.2×	20	1.5k
Qiyu Sun China	14	1.5k 1.0×	637 1.7×	272 1.3×	174 1.1×	138 1.0×	25	2.0k
Ray T. Y. So Hong Kong	9	1.2k 0.8×	345 0.9×	215 1.0×	135 0.8×	209 1.6×	17	1.4k
Liyuan Liu China	12	1.1k 0.7×	379 1.0×	141 0.7×	263 1.6×	137 1.0×	23	1.5k
Kerri St. Denis United States	12	1.7k 1.2×	486 1.3×	233 1.1×	291 1.8×	102 0.8×	18	1.9k
Rüdiger Groß Germany	14	926 0.6×	301 0.8×	116 0.6×	168 1.1×	117 0.9×	35	1.3k
Jonathan Daniel Ip Hong Kong	18	1.3k 0.9×	247 0.7×	95 0.5×	99 0.6×	90 0.7×	35	1.6k

Countries citing papers authored by Amy Kempf

Since Specialization

Citations

This map shows the geographic impact of Amy Kempf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Kempf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Kempf more than expected).

Fields of papers citing papers by Amy Kempf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Kempf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Kempf. The network helps show where Amy Kempf may publish in the future.

Co-authorship network of co-authors of Amy Kempf

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Kempf. A scholar is included among the top collaborators of Amy Kempf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Kempf. Amy Kempf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Lu, Amy Kempf, Inga Nehlmeier, et al.. (2025). Neutralizing activity against bovine H5N1 HPAIV (clade 2.3.4.4b) in human plasma after seasonal influenza vaccination. Emerging Microbes & Infections. 14(1). 2528539–2528539. 2 indexed citations

Miller, Gavin J., Amy Kempf, Inga Nehlmeier, et al.. (2025). Polyvalent Mannuronic Acid-Coated Gold Nanoparticles for Probing Multivalent Lectin–Glycan Interaction and Blocking Virus Infection. Viruses. 17(8). 1066–1066.

Arora, Prerna, Amy Kempf, Inga Nehlmeier, et al.. (2025). Entry Efficiency, Protease Dependence, and Antibody-Mediated Neutralization of SARS-CoV-2 Sublineages KP.3.1.1 and XEC. Vaccines. 13(4). 385–385. 1 indexed citations

Zhang, Lu, Amy Kempf, Inga Nehlmeier, et al.. (2025). Host cell entry efficiency and neutralization sensitivity of the SARS-CoV-2 MC.10.1 variant. Virology. 612. 110675–110675. 1 indexed citations

Arora, Prerna, Lu Zhang, Inga Nehlmeier, et al.. (2025). Host cell lectins ASGR1 and DC-SIGN jointly with TMEM106B confer ACE2 independence and imdevimab resistance to SARS-CoV-2 pseudovirus with spike mutation E484D. Journal of Virology. 99(2). e0123024–e0123024. 1 indexed citations

Schulz, Sebastian, Amy Kempf, Inga Nehlmeier, et al.. (2024). Comparative Analysis of Host Cell Entry Efficiency and Neutralization Sensitivity of Emerging SARS-CoV-2 Lineages KP.2, KP.2.3, KP.3, and LB.1. Vaccines. 12(11). 1236–1236. 2 indexed citations

Zhang, Lu, Alexandra Dopfer‐Jablonka, Inga Nehlmeier, et al.. (2024). Virological Traits of the SARS-CoV-2 BA.2.87.1 Lineage. Vaccines. 12(5). 487–487. 2 indexed citations

Kempf, Amy, Inga Nehlmeier, Nicole Hondow, et al.. (2024). Probing scaffold size effects on multivalent lectin–glycan binding affinity, thermodynamics and antiviral properties using polyvalent glycan-gold nanoparticles. Nanoscale. 16(29). 13962–13978. 1 indexed citations

Jacobsen, Henning, Markus Hoffmann, Amy Kempf, et al.. (2023). TMPRSS2 Is Essential for SARS-CoV-2 Beta and Omicron Infection. Viruses. 15(2). 271–271. 38 indexed citations

10.

Hoffmann, Markus, Lok-Yin Roy Wong, Prerna Arora, et al.. (2023). Omicron subvariant BA.5 efficiently infects lung cells. Nature Communications. 14(1). 3500–3500. 21 indexed citations

11.

Sidarovich, Anzhalika, Nadine Krüger, Cheila Rocha, et al.. (2022). Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1. Viruses. 14(11). 2475–2475. 1 indexed citations

12.

Arora, Prerna, Lu Zhang, Cheila Rocha, et al.. (2022). The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant. International Journal of Molecular Sciences. 23(22). 14057–14057. 4 indexed citations

13.

Wettstein, Lukas, Tatjana Weil, Carina Conzelmann, et al.. (2022). Native and activated antithrombin inhibits TMPRSS2 activity and SARS‐CoV‐2 infection. Journal of Medical Virology. 95(1). e28124–e28124. 18 indexed citations

14.

Arora, Prerna, Amy Kempf, Inga Nehlmeier, et al.. (2022). SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination. Cell Reports. 39(5). 110754–110754. 4 indexed citations

15.

Hoffmann, Markus, Heike Hofmann-Winkler, Nadine Krüger, et al.. (2021). SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell Reports. 36(3). 109415–109415. 162 indexed citations

16.

Arora, Prerna, Cheila Rocha, Amy Kempf, et al.. (2021). The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency. Cellular and Molecular Immunology. 18(12). 2673–2675. 29 indexed citations

17.

Arora, Prerna, Anzhalika Sidarovich, Nadine Krüger, et al.. (2021). B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination. Cell Reports. 37(2). 109825–109825. 56 indexed citations

18.

Hoffmann, Markus, Prerna Arora, Rüdiger Groß, et al.. (2021). SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 184(9). 2384–2393.e12. 563 indexed citations breakdown →

19.

Hoffmann, Markus, Lu Zhang, Nadine Krüger, et al.. (2021). SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. Cell Reports. 35(3). 109017–109017. 59 indexed citations

20.

Hoffmann, Markus, Nadine Krüger, Sebastian Schulz, et al.. (2021). The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell. 185(3). 447–456.e11. 557 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact